- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Del spells relief SEC
The Securities and Exchange Commission has relieved Del Global Technologies from requirements to file selected financial data for fiscal years 1999 and 1998. Consequently, the beleaguered maker of x-ray equipment need file only three years of financial
The Securities and Exchange Commission has relieved Del Global Technologies from requirements to file selected financial data for fiscal years 1999 and 1998. Consequently, the beleaguered maker of x-ray equipment need file only three years of financial data rather than five. Del executives successfully argued that they could not prepare reliable statements of operations for FY 1999 and 1998 due to a turnover in personnel and the absence of records. With this, the company can now file a form S-1 registration statement with the SEC covering the issuance of one million shares underlying the warrants issued by Del as part of a shareholder class action suit. The SEC must review and declare effective the issuance of shares.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
